
Opinion|Videos|July 22, 2024
Real-World Data for Risdiplam in Adult Patients with Spinal Muscular Atrophy
Panelists examine the available real-world data (RWD) on the use of risdiplam in adult patients with spinal muscular atrophy (SMA) from various studies conducted worldwide, discussing its potential efficacy and safety as a treatment option for adult SMA patients.
Advertisement
Episodes in this series

- Discuss real-world evidence for risdiplam in adult patients.
Newsletter
Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Caregiver Decision-Making for Duchenne Gene Therapy Use Requires Collaborative Input, Thoughtful Consideration
2
FDA Action Update, October 2025: Clearance, Acceptance, and Extension
3
Study Shows Caregivers Willing to Discuss Social Determinants of Health in Pediatric Multidisciplinary Clinics
4
Simplifying Narcolepsy Treatment: Insights on Once- vs. Twice-Nightly Oxybate
5




































